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1. Introduction
Transplantation is one of the revolutionary fields in modern medicine that has saved thou‐
sands of lives. The continuous refinement of surgical techniques and the availability of potent
immunosuppressive drugs have made transplantation the most effective treatment option for
patients with end stage organ failure. Over 25 000 organ transplants are performed in the USA
each year and survival rates following transplantation are now approaching 90% at 1 year and
75% at 5 years, depending on the organ transplant (kidney, liver, pancreas, heart, lung,
intestine). Central to this success was the introduction of drugs that suppress the immune
system and prevent rejection. Indeed, across organs, the use of current immunosuppression
regimens effectively prevents acute rejection in the majority of patients. As a result, the
incidence of graft loss due to acute rejection has decreased dramatically compared to the early
era of transplantation.
This success of organ transplantation has led to a growing population of immunosuppressed
transplant recipients with prolonged survival with a functioning graft, but also with prolonged
exposure to the side effects and complications of chronic immunosuppression. Indeed, the
burden of chronic immunosuppression post-transplant has become a growing concern among
transplant physicians, although its impact is currently smaller compared to two decades ago,
following the introduction of new and less-toxic immunosuppression regimens (see below).
However, chronic immunosuppression remains associated with significant morbidity: as an
example, the majority of patients treated with calcineurin inhibitors develop some degree of
renal function impairment and up to 10% progress to kidney failure requiring dialysis or
kidney transplant (see below).
The consequences of chronic immunosuppression on multiple organ systems are becoming
increasingly evident and often new symptoms or disorders develop post-transplant as a
consequence of the side-effects of immunosuppressive drugs (ie opportunistic infections,
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malignancies, diabetes mellitus, hypertension and others, see below). The onset of new post-
transplant conditions requiring treatment has multiple implications in terms of function of the
graft, patient compliance and cost. Therefore, strategies to limit and prevent the complications
of prolonged immunosuppression post-transplant are needed.
Here we present briefly the most common immunosuppression regimens currently used in
abdominal organ transplantation and we review current major complications and challenges
of prolonged immunosuppression after transplant. We will discuss issues common to ab‐
dominal organ transplants including liver, intestine, pancreas, kidney, without entering into
organ-specific issues. The discussion is limited to adult transplant recipients, since pediatric
transplantation raises a number of issues specific to this age group in terms of immunosup‐
pression regimens and its complications including growth-related issues and compliance. In
addition, a pediatric transplant recipient has potentially an expected more prolonged exposure
to chronic immunosuppression than an adult and, as a consequence, more time to develop
complications.
We will also present current strategies in the management of complications of immunosup‐
pression and ways to limit the burden of immunosuppression. Finally, we report on current
research and indicate future directions to improve post-transplant immunosuppression.
2. Current immunosuppression regimens in abdominal organ
transplantation
Compared to the early era of transplantation, a substantial progress has been made since the
early 1990s in developing effective immunosuppressive agents to prevent allograft rejection.
As a result, graft and patient survival rates have dramatically improved. In addition, highly
immunogenic organs such as heart, lungs and intestine, previously characterized by a high
incidence of failure due to rejection, are now being successfully transplanted since more potent
immunosuppressive drugs have become available.
Most immunosuppressive agents target T lymphocytes, which are primary mediators of the
alloimmune response and effectors of the rejection process. Current immunosuppression
protocols usually include two or more agents to target different steps or mechanisms of the
alloreactive immune response. The combination of multiple drugs not only increases the
efficacy of the immunosuppression regimen but also often allows dose reduction of one or more
of the drugs in an attempt to limit the associated toxicity (see below). Recently, other agents
have been introduced that target B lymphocytes and other mechanisms involved in the
alloimmune response including complement and others mechanism of the innate immune
system (see below). As a result, an increasing number of immunosuppressive agents are now
available (Table 1).
There are also new drugs being evaluated in clinical trials that target novel mechanisms and
pathways of the immune response in attempt to reduce the burden of side effects and com‐
plications of agents currently available [1,2].
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Immunosuppression is usually heavier in the peri-operative period and early post-transplant
(induction) when the risk of rejection is higher due to a number of factors including preser‐
vation injury of the graft and sudden exposure of the recipient immune system to a load of
foreign antigen. Later, depending on graft function and tolerability, immunosuppressive doses
are gradually reduced (maintenance) to levels adequate to prevent rejection and avoid toxicity.
Although there are reports of “tolerant” patients, who maintain a functioning graft after
discontinuation of immunosuppression) (see below), these are rare and exceptional cases and
immunosuppression needs to be continued lifelong, inevitably exposing the recipient to the
long term effects of chronic immunosuppression. Since the is no single optimal immunosup‐
pression regimen, post-transplant care strives to achieve the delicate balance between effective
prevention of rejection and avoidance of toxicity. The doses of immunosuppressive drugs are
usually adjusted according to target trough levels, which vary among organs and among
transplant programs.
2.1. Antibodies
Polyclonal antithymocyte globulins (Atgam, Thymoglobulin) are prepared from the serum of
rabbits immunized with human thymocytes. Antithymocyte globulins contain cytotoxic
antibodies that bind to CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45 and HLA class
I and II molecules on the surface of human T lymphocytes. The mechanism of action of
depleting antibodies is to reduce the number of circulating lymphocytes by direct cytotoxicity,
both complement and cell-mediated. Anti-CD3 monoclonal antibodies (OKT3) is a mouse
monoclonal antibody against CD3. It binds to T-cell receptor-associated CD3 complex and
depletes and alters T-cells. Its use has declined since newer immunosuppressive drugs have
reduced the incidence of rejection episodes.
Non-depleting antibodies (Basiliximab, Daclizumab) block lymphocyte function by binding
to cell surface molecules involved in the regulation of cell function. The main uses of antibodies
in post-transplant immunosuppression are during induction and for the treatment of severe
or steroid-resistant rejection (review in [3]). The risk of opportunistic infections (viral, fungal)
is higher after profound T cell depletion, especially if prolonged, compared to the use of non-
Antibodies Alemtuzumab, Atgam, Basiliximab, Daclizumab, OKT3, Thymoglobulin
Antimetabolites Azathioprine, Mycophenolate mofetil, Mycophenolate sodium
Calcineurin-inhibitors Cyclosporine, Tacrolimus, Voclosporine
Corticosteroids Methylprednisolone, Prednisone
Co-stimulation blockers Belatacept
Proliferation- inhibitors Everolimus, Sirolimus
Others Bortezomib, Infliximab, Rituximab
Table 1. Immunosuppressive agents currently available
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depleting agents. Adverse effects include fever, chills, thrombocytopenia, leukopenia,
hemolysis, respiratory distress, serum sickness, and anaphylaxis.
2.2. Antimetabolites
Azathioprine, a derivative of 6-mercaptopurine functioning as an antimetabolite to decrease
DNA and RNA synthesis, has been used for many years since the early era of organ trans‐
plantation in combination with corticosteroids. The mechanism of action of azathioprine is to
incorporate into and to halt DNA replication by blocking the de-novo purine synthesis in
lymphocytes. Adverse effects include myelosuppression (leukopenia, thrombocytopenia),
nausea, vomiting, diarrhea, hepatitis, cholestasis and alopecia. In the last 10 years azathioprine
has been largely replaced by mycophenolate mofetil and mycophenolate sodium (two
preparations of mycophenolic acid) in many transplant programs.
Mycophenolic acid. Unlike other cell types that can “recycle” purines from the process of cell
turnover, lymphocyte proliferation and responses are dependent on the de novo purine
synthesis; mycophenolic acid blocks the action of the key enzyme inosine monophosphate
dehydrogenase (IMPDH), a rate limiting step in the biosynthesis of purines crucial to cell
cycling in T and B lymphocytes. Consequently, the proliferation and clonal expansion of T and
B lymphocytes is prevented, with the effect of reducing the alloreactive immune response,
including antibody production and the generation of cytotoxic T cells and other effector cells.
In addition, mycophenolic acid suppresses the glycosylation and the expression of adhesion
molecules, thereby decreasing recruitment of lymphocytes and monocytes into sites of
inflammation and graft rejection.
Two  formulations  of  mycophenolic  acid  are  now  available,  mycophenolate  mofetil  and
mycophenolate  sodium.  Both  formulations  are  non-nephrotoxic  and  are  being  used  in
calcineurin-inhibitors sparing regimens in attempt to reduce the risk of renal failure (see
below).  The  main  side  effects  of  mycophenolate  mofetil  are  gastro-intestinal  intolerance
(diarrhea), reported in up to 45% of patients and often requiring dose reduction or discontin‐
uation. The enteric-coated mycophenolate sodium was designed to reduce the mycophenol‐
ic acid-related gastro-intestinal adverse effects: the enteric coating dissolves at pH levels ≥5,
thus  delaying  the  delivery  of  the  active  compound mycophenolate  acid  until  the  small
intestine.
2.3. Calcineurin-inhibitors
The most commonly used class of immunosuppressive drugs currently used in organ trans‐
plantation are calcineurin inhibitors (CNIs). Indeed, calcineurin inhibitors (cyclosporine and
tacrolimus) are main immunosuppressive agents in use today in virtually every transplant
program. Their immunosuppressive effect results from the blockage of the production of pro-
inflammatory cytokines including IL-2, INF-γ, TNF-α and from inhibition of T cell activation
and proliferation. Their mechanism of action is to inactivate calcineurin, an essential enzyme
for the function of T cell lymphocytes. Calcineurin, an intracellular calcium/calmodulin
phosphatase triggered by the engagement of T cell receptor by donor MHC, dephosphorilates
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nuclear factor for activated T cells (NF-AT) which in turn promotes the transcription of
cytokine genes. The main adverse effect associated with the use of CNI is renal function
impairement: virtually all people who take a CNI will develop some degree of kidney toxicity
and up to 10% will progress to kidney failure. With more people taking CNIs for longer and
longer periods of time the consequences of calcineurin inhibition on other organ systems -
particularly kidney function - have become a growing concern. In addition to nephrotoxicity,
other adverse effects of CNI include hyperkalemia, hypomagnesemia, nausea, vomiting,
diarrhea, hypertrichosis, hirsutism and gingival hyperplasia. Tacrolimus, a more potent CNI
compared to cyclosporine, shares the same mechanism of action and the same risk of nephro‐
toxicity. Tacrolimus binds to a cytoplasmic protein FK506-binding protein 12 (FKBP12) to
create a complex that inhibits phosphatase activity of calcineurin. Tacrolimus, like CsA,
inhibits signal transduction pathways linked to the T-cell receptor for antigen at the level of
JNK and p38 kinase. While the abnormal cosmetic side effects (hypertrichosis and hirsutism)
are less frequent with tacrolimus compared to cyclosporine, glucose intolerance and neuro‐
toxicity (headache, seizures) are more common. Voclosporin, a cyclosporine analog with
reduced nephrotoxicity, is a novel calcineurin inhibitor being developed for organ transplan‐
tation and currently in clinical trials: preliminary results showed a reduced risk of post-
transplant diabetes compared to tacrolimus while maintaining the same efficacy in preventing
rejection in kidney transplantation [4].
2.4. Corticosteroids
Corticosteroids (methylprednisolone, prednisone) were the first immunosuppressive drugs to
be used in transplantation and remain today first line treatment across organs for both
prevention and treatment of rejection. The multiple anti-inflammatory and immunomodula‐
tory effects on a wide variety of cells including lymphocytes, granulocytes, macrophages,
monocytes and endothelial cells are well known and the molecular mechanisms of action of
steroids have been described extensively [5]. Briefly, corticosteroids down regulate cytokine
gene expression in lymphocytes, antagonize macrophage differentiation, inhibit neutrophil
adhesion to endothelial cells thereby decreasing their extravasation to the site of inflammation,
decrease circulating eosinophil and basophil counts, inhibit IgE-dependent release of hista‐
mine and leukotriene from basophils and inhibit degranulation of mast cells. Additionally,
glucocorticoids downregulate endothelial cell function including expression of class II MHC
antigen and expression of adhesion molecules. Based on these multiple effects on different
cellular components of the immune response corticosteroids are very effective in preventing
and treating acute allograft rejection, although there are instances of steroid-resistant rejection
episodes. The multiple side effects of steroids are also well known and include impaired
wound healing, increased risk of infection, hypertension, weight gain, hyperglycemia,
osteoporosis, fluid retention, hirsutism, acne and cataracts. Side effects may have an important
impact especially in the long term and in children (ie growth pattern), therefore multiple trials
of steroid withdrawal and steroid-free regimens have been designed in an attempt to limit the
side effects of corticosteroids.
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2.5. Costimulation blockers
Costimulation blockers represent a new class of immunosuppressants with a different
mechanism of action compared to calcineurin inhibitors [6]. Costimulation (or signal 2) refers
to the amplifying signal received by the T lymphocyte after interaction with ligands presented
by antigen presenting cells. This costimulation amplifies the initial T cell activation event (or
signal 1) resulting from the engagement of T cell receptors with donor antigens. Indeed, T cells
undergoing signal 1 without signal 2 become unresponsive and undergo apoptosis. Several
costimulatory pathways mediate the interactions between the surface of T cells and antigen
presenting cells. One of the most studied pathways involves the surface molecule CD28 on
lymphocytes and the B7 family of molecules on antigen presenting cells. This signaling
pathway has become an attractive target for the development of novel immunosuppressive
drugs. Two humanized fusion proteins have been developed to inhibit costimulatory signal‐
ing, abatacept and belatacept. The latter has been used in clinical kidney transplantation [7].
2.6. Proliferation inhibitors (mTOR-inhibitors)
This group includes everolimus and sirolimus, two of the most recently introduced immuno‐
suppressive agents in clinical transplantation, acting with a mechanism of action different from
calcineurin-inhibitors and from antimetabolites. Sirolimus will be discussed first, being the
first mTOR inhibitor to be used in clinical transplantation. Sirolimus (also known as rapamy‐
cin) is a bacterial macrolide antibiotic produced by a strain of Streptomyces hygroscopicus
isolated from a soil sample collected from the island Rapi Nui, commonly known as Easter
Island. Although originally an antifungal agent with potent anti-candida activity, side effects
precluded its use as an antifungal, and it has since been used primarily as an immunosup‐
pressant. Sirolimus and everolimus are members of a newer class of immunosuppressive
agents called inhibitors of the mammalian target of rapamycin. Sirolimus binds the intracel‐
lular immunophilin FKB12, the same intracellular binding protein of tacrolimus, but with
different mechanism of action. After binding the immunophilin, the complex sirolimus-
immunophilin inhibits a protein called mammalian target of rapamycin (mTOR). Inhibition of
mTOR results in selective inhibition of synthesis of new ribosomal proteins which are essential
for progression of the cells from the G1 to the S phase. This results in blockage of T cell
activation. In addition, sirolimus has been associated with inhibition of fibroblast growth
factors required for tissue repair. The half life of sirolimus is 60 hours which allows single daily
dose unlike other agents given twice daily and this has an important impact on patient
compliance to immunosuppression regimens. Everolimus is a modified form of sirolimus to
improve its absoprion. Its half life is shorter and is administred twice daily. Everolimus is
currently undergoing clinical trials in transplantation in attempt to reduce the nephrotoxicity
of calcineurin inhibitors [8,9]. The adverse effects of mTOR inhibitors include thrombocyto‐
penia, leukopenia, anemia, arthralgias, hyperlipidemia, pneumonitis, and diarrhea. There
have also been reports of wound complications (delayed wound healing, incisional hernia) in
the post-transplant period, an affect probably secondary to its antiproliferative effects on
fibroblasts. Oral ulcers were seen with the liquid preparation; however, this seems to be less
frequent with the use of the pill preparation.
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2.7. Other novel immunosuppressive agents
In this group we include antibodies that act on different targets than T cells. Bortezomib is an
antineoplastic agent originally developed for the treatment of multiple myeloma. It is a
proteasome inhibitor that induces apoptosis in rapidly dividing cells with active protein
synthesis like plasma cells. In kidney transplantation it has been reported to revert antibody-
mediated rejection [10]. Anti–tumor necrosis factor (TNF) reagents (Infliximab) are monoclo‐
nal antibodies that bind with high affinity to TNF-alpha and prevent the cytokine from binding
to its receptors. It is approved for treating the symptoms of rheumatoid arthritis. In transplan‐
tation it has been investigated in the treatment of severe rejection after intestinal transplanta‐
tion [11]. Rituximab is a monoclonal antibody directed against the CD20 antigen on B cells. It
is approved for the treatment of certain types of non-Hodgkin lymphoma and to reduce the
signs and symptoms of moderate to severe rheumatoid arthritis. In transplantation its use is
currently being studied in treating some forms of antibody-mediated rejection [12] and as part
of desensitization protocols in highly sensitized transplant recipients [13].
3. Complications of prolonged immunosuppression post-transplant
As a result of the success of effective immunosuppression, many more transplant recipients
live now longer after transplant compared to decades ago and have time to manifest the long
term effects of chronic immunosuppression. This has become increasingly more evident with
the longer follow-up of successful transplant recipients. Indeed, after achieving excellent
survival rates across organs, a constant focus of research and current clinical trials are now
concentrating on how to reduce or prevent or antagonize the burden of chronic immunosup‐
pression. It is becoming increasingly clear that if an effective control of rejection on the one
hand protects the graft function and prolongs patient survival, at the same time the patient is
exposed to the risk of complications of prolonged immunosuppression and also to new post-
transplant disease, even in presence of excellent graft function. These complications result from
either persistently low immune defenses as a result of immunosuppressive therapy (infections
and malignancies) or as a result of side effects of immunosuppressive drugs, which affect
virtually every organ system (renal function impairment, diabetes, cardiovascular disease and
others, see below).
3.1. Infections
The most obvious consequence of a decreased immune defense is the increased risk of
infection. Indeed, infectious complications are among the most common causes of morbidity
and mortality after transplantation. Improved immunosuppressive regimens, while reducing
the incidence of allograft rejection, have increased the susceptibility to opportunistic infections.
In addition, other factors including malnutrition, co-morbidities associated with end stage
renal or liver disease and alterations of the muco-cutaneous barriers following the transplant
procedure contribute to increase the risk of infections post-transplant. Post-transplant
infections have been classified in 1.peri-operative infections (during the first month post-
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transplant, usually nosocomial infections or donor-derived), 2. early post-transplant infections
(within the first 6 months, usually due to reactivation of latent infections, mostly viral) and 3.
late infections (occurring usually after 6 months from transplant, mainly community acquired
infections) [14]. Strategies to prevent infections post-transplant are based on either universal
prophylaxis (administration of antimicrobial therapy to all patients at risk of infection for a
limited period, usually 3 to 6 months post-transplant) or pre-emptive therapy (monitoring
patients at established intervals for early detection and treatment of infection). A large number
of viruses, bacteria and fungi can cause significant infections post-transplant. Here we discuss
the most common viral, bacterial and fungal infections post-transplant.
3.2. Viral infections
The most common viral infections post-transplant are caused by viruses listed in Table 2.
Adenovirus
Cytomegalovirus (CMV)
Epstein-Barr virus (EBV
Herpes simplex (HSV)
Influenza-Parainfluenza
Polyoma (BK)
Rotavirus
Varicella-zoster virus
Table 2. Viral infections post-transplant
Cytomegalovirus and Epstein-Barr virus, among others, are causing significant morbidity
post-transplant and will be discussed here.
3.2.1. Cytomegalovirus [15,16]
The incidence of CMV infection post-transplant (ie detection of active viral replication in the
recipient) ranges from 25 to 50%, depending on the organ [17] The incidence of CMV disease
(ie organ damage by CMV infection) is lower, reported between 3 and 14% [18]. The main risk
factors for CMV infection and disease include serology mismatch (donor CMV IgG positive,
recipient CMV IgG negative), degree of imunosuppression, use of antilymphocyte antibodies
for the treatment of rejection and the type of graft (more common in lung and intestinal
transplant, likely related to the heavy immunosuppression regimens used in these recipients.
Manifestations of CMV disease vary from flu-like symptoms to invasive organ disease. Most
commonly affected are the gastrointestinal tract (ulcers), the lungs (pneumonitis) and the liver
(hepatitis). The morbidity associated with CMV post-transplant is not only related to its direct
effects (see above) but also to its indirect effects, including increased risk of rejection, of other
infections and of EBV-related lymphoproliferative disorders [19] (see below). Prophylaxis of
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CMV is usually with either intravenous ganciclovir or with oral valgancyclovir, an oral
prodrug of ganciclovir with equivalent drug exposure [18]. Standard treatment of invasive
disease usually requires intravenous ganciclovir for 2-3 weeks, often extended for a longer
period to treat severe disease. Foscarnet and cidofovir are alternative agents active on CMV
but are rarely used because of their toxicity
3.2.2. Epstein-Barr virus [20, 21]
EBV is a DNAvirus associated with the common, usually self-limited infectious mononucleosis
affecting young immunocompetent subjects. In the transplant recipient EBV infection may
cause significant morbidity and mortality related to the development of post-transplant
lymphoproliferative disorders (PTLD). EBV transforms and immortalizes B cell, which
proliferate uncontrolled when the surveillance of EBV immunocompetent T cells is lacking
secondary to immunosuppression. EBV infection post-transplant occurs either as primary
infection, especially in children, or as reactivation. Risk factors for PTLD include primary EBV
infection in a seronegative transplant recipient, the net state of immunosuppression (especially
the use of antilymphocyte antibodies) and prior CMV infection. Quantitative EBV viral load
assays are used for surveillance, diagnosis and disease monitoring. Non-PTLD manifestations
of EBV disease post-transplant vary from mononucleosis-like viral syndrome to organ
involvement (lungs, liver, gastrointestinal tract, bone marrow). PTLD presents a wide
spectrum of histology and clinical presentations, from benign self-limited lymphoproliferation
to aggressive disseminated lymphoma [22]. These lymphoproliferation are commonly
extranodal and the transplanted organ may be involved as well. Outside the allograft, typical
sites of involvement include the liver, gastrointestinal tract, skin and central nervous system.
The incidence of PTLD varies across organs from 1-5 % in kidney and liver transplant to as
high as 15-20% in intestinal transplant recipients [23]. Based on morphologic, immunopheno‐
typic, and molecular criteria, PLTD are classified into 4 pathologic categories: early lesions,
polymorphic, monomorphic, and classical Hodgkin lymphoma.They present with a wide
spectrum of pathologic and clinical manifestations ranging from benign lymphoid hyperplasia
to aggressive lymphomas. Given the pathologic and clinical heterogeneity of PTLD, treatment
is often individualized. Although there is no generally accepted protocol, treatment includes
reduction or discontinuation of immunosuppression and a combination of rituximab (a
chimeric anti-CD20 monoclonal antibody), chemotherapy, antiviral therapy and surgical
resection depending on the aggressivity (review in [20] and [24]). New strategies are being
tried such as adoptive immunotherapy [25].
3.3. Bacterial infections
The most common bacterial infections post-transplant are listed in Table 3.
The majority of bacterial infections early post-transplant (first month) are hospital acquired
and are usually characterized by a high incidence of multidrug-resistance (review in [26]).
Opportunistic bacterial infections, usually occurring between 2 and 6 months post-trasnplant,
are caused by Listeria monocytogenes and Nocardia spp. Six months after transplant or later,
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when immunosuppression is generally lowered, community-acquired bacterial infections are
the most common, especially urinary tract infections by E. coli and S. pneumonia pneumonia.
Gram negative
Bacteroides and other anaerobes
Enteric bacteria
Pseudomonas
Gram positive
Staphylococcus spp
Streptococcus spp
Enterococcus spp (incl VRE)
Table 3. Common bacteria of post-transplant infections
Common bacterial infections post-transplant affect the urinary tract, the respiratory tract, the
surgical wound and the bloodstream. The incidence of bacterial urinary tract infections ranges
between 4.4% in non renal transplant recipients and 7% in renal transplant recipients, most
commonly secondary to E. coli [27]. In one study the need for immediate post-op dialysis was
risk factor for bacterial urinary tract infection in kidney transplant recipients, whereas age and
diabetes were main risk factors in non renal transplant recipients [27].
Skin and wound infections, although not life-threatening, are common after solid organ
transplantation. One study reported an incidence up to 45 % in kidney-pancreas recipients [28].
Most common isolates are S. aureus, but also enteric gram negative bacteria in abdominal organ
recipients. The incidence of pneumonia also varies between organs from 7.3% within the first
year after kidney transplant [29] to 22% after liver transplant [30] to 36% in lung transplant
recipients [31] and is associated with prolonged intensive care stay and hospital stay. The
source of bacterial bloodstream infections after transplant, in addition to intravenous catheters,
include the respiratory tract, the urinary tract and the abdomen. However, often the source of
bacteremia is not identified. Both Gram negative and Gram positive bacteria are isolated but
in recent years methicillin-resistant staphylococci and vancomycin-resistant enterococci have
become more common [32]. The presence of polymicrobial infection, the early onset of
bacteremia after transplantation, the association with pneumonia, liver failure or kidney
failure increase the mortality risk associated with bacteremia, reported up to 25% in lung
transplant recipients [33].
3.4. Fungal infections
Fungal infections post-transplant cause significant morbidity and increase the mortality risk
(review in [34]). Candida spp. and Aspergillus spp. are the most common causes of invasive
fungal infections after transplant.
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Aspergillus spp.
Candida spp
Cryptococcus spp
Hystoplasma capsulatum
Table 4. Most common fungal infections post transplant
The incidence of invasive fungal infections varies across organs between 7 and 14% in pancreas
transplant, 5-42% in liver transplant, 15 to 35% in lung transplant and 40-59% in intestinal
transplant [35]. There are multiple risk factors related to the net state of immunosuppression
(high doses of corticosteroids, use of antibody induction) and peri-operative factors such as
prolonged complex operations including re-transplantation and renal dysfunction [36]. In
addition, concomitant viral infections (ie CMV) exert immunomodulatory and immunosup‐
pressive effects that increase the risk of fungal infections [37]. The clinical manifestations of
invasive Candida infection vary across organs and include wound, intra-abdominal (perito‐
nitis), thoracic (tracheobronchitis, pneumonitis) and bloodstream infection. The majority of
cases of invasive Aspergillosis involve the lungs with single or multiple nodular infiltrate that
may become cavitary lesions (Figure 1)
Figure 1. Pulmonary aspergillosis
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The second and most invalidating site of invasive aspergillosis is intracranial, causing mental
status alterations, seizures and focal neurologic deficits secondary to brain abscesses that most
commonly involve the fronto-parietal lobes. The angiotropic character of Aspergillus infection
tends to cause vascular invasion resulting in intracranial infarcts or hemorrhagic lesions
(Figure 2)
Figure 2. Intracranial aspergilloma
The overall 3 month mortality risk from invasive fungal infections after transplant across
organs has been reported up to of 29% [34] and key strategies remain prophylaxis of high risk
recipients and early diagnosis and prompt treatment.
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3.5. Malignancies
In addition to increased risk of infections, chronic suppression of the immune defences is
associated with increased risk of malignancies. The incidence has been reported 3- to 5-fold
higher in transplant recipients than in the general population and increases with the length of
follow up. It has also been reported that after 25 years of immunosuppression, about half of
the recipients are at risk of developing some kind of tumor [38]. Indeed, in renal transplant
recipients, cancer is the third most common cause of death after cardiovascular accidents and
infections [39].
Squamous and basal cell carcinomas of the skin are the most common de-novo malignancies,
accounting for almost half of cancers post-transplant, although recently melanoma has been
re-emphasized as also having an increased frequency following transplantation. The ratio of
squamos and basal cell carcinoma is 4:1, the opposite of what is found in the immunocompetent
population. Squamous cell carcinoma is more aggressive in transplant recipients compared to
the general population, tends to recur and occasionally to metastasize [40]. Risk factors for skin
cancer post-transplant, in addition to prolonged immunosuppression, are age, skin type and
exposure to ultraviolet radiation. Therefore, attempts are made to reduce the dose of mainte‐
nance immunosuppression after developing skin cancer and to reduce skin exposure and to
seek dermatology yearly survey in order to reduce the risk of recurrence. In addition, clinical
data have shown beneficial effects of the use of mTORinhibition (sirolimus, see above) in
preventing cancer development in transplant recipients. It is likely that these effects are the
result of sirolimus’antitumor and antiangiogenic properties [41]. The second most common
group of malignancies after transplant are lymphoproliferative disorders (PTLD), usually
Epstein-Barr Virus-induced (see above, review in [42]). Excluding skin cancer and lympho‐
proliferative disorders, the incidence of de-novo malignancies (gastrointestinal, pulmonary and
others) has been reported between 0.7% and 5.6% at 5 years [43]. A more recent study reported
that the risk of de-novo malignancies after liver transplantation is 2-3 times higher than the
general population [44].
3.6. Renal dysfunction
The effects of immunosuppressive drugs extend far beyond lowering the immune defense of
transplant recipients and have an impact on virtually every organ system. Among them, renal
dysfunction is a common and significant complication of solid organ transplantation. Long-
term use of calcineurin inhibitors as part of immunosuppressive regimens is considered to be
a major contributing factor in the development of chronic kidney disease (CKD). Renal failure
post-transplant is associated with a 4-fold increase in mortality risk [45]. The incidence of renal
dysfunction varies across organs depending on the length and level of calcineurin-inhibitors
based immunosuppression. The mechanism of nephrotoxicity, like in hypertension, is thought
to be related to alterations of the vascular tone of the endothelium at the level of the afferent
arteriole [46]. However, CNI cause both acute and chronic nephrotoxicity. Acute nephrotox‐
icity involves afferent arteriolar vasoconstriction and reduced renal plasma flow, and is
predictably associated with high trough levels. In contrast, chronic CNI-induced nephrotox‐
icity is not predicted by individual trough levels, and is characterized by potentially irrever‐
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sible structural changes including arteriolopathy, tubulointerstitial fibrosis and, eventually,
glomerulosclerosis. Among other factors implicated in renal dysfunction post-transplant are
hypertension, diabetes, pre-transplant renal function impairment and post-transplant acute
kidney injury [47]. Several strategies have been proposed in attempt to reduce the risk of
nephrotoxicity post-transplant, including CNI reduction or avoidance (review in [48]) and
conversion to mycophenolate mofetil-based [49] or sirolimus- based [50] immunosuppression
regimens. Although there is no general consensus on the optimal combination of immunosup‐
pressive agents for maintenance of graft function while minimizing nephrotoxicity, it has
become increasingly evident that immunosuppression regimens may need to be individualized
based on patient- and organ-specific factors (see below).
3.7. Cardiovascular disease
Post-transplant, several preexisting risk factors like hypertension, dyslipidemia and hypergly‐
cemia usually get  exacerbated resulting in accelerated atherosclerosis  causing significant
cardiovascular disease post-transplant, including ischemic heart attack, congestive heart failure,
cerebrovascular accidents and peripheral vascular disease. Indeed, cardiovascular disease is the
most common cause of death in transplant patients, with a 2.5-fold greater risk of cardiovascu‐
lar mortality and threefold greater risk of ischemic events compared to the general population
[51]. Prevention strategies to limit the impact of cardiovascular disease after transplant include
lifestyle modifications, correction of modifiable risk factors (hypertension, diabetes mellitus and
dyslipidemia, see below) and tailoring of immunosuppression [52].
3.8. Hypertension (review in [53])
De- novo hyprtension post-transplant or the acceleration of hypertension (>140/90 mmHg) is
common after solid organ transplantation, affecting up to 50%- 75% of patients within the first
weeks to months [54] and can pose a significant hazard both early and late after transplant.
Both calcineurin inhibitors cyclosporine and tacrolimus have been associated with develop‐
ment or worsening hypertension post-transplant [55]. Since CNI based immunosuppression
regimens are very common in virtually every transplant program, is it no surprise that
hypertension remains a major cardiovascular risk factor in organ transplant recipients. CNIs
are known to increase sympathetic tone, vasoconstriction and to cause sodium dependent
volume expansion [56]. Studies have demonstrated the beneficial effect of lowering blood
pressure post-transplant and the association of controlled blood pressure with prolonged
patient and graft survival [57].
3.9. Diabetes mellitus
New-onset diabetes after transplantation (NODAT) refers to the occurrence of diabetes in
previously non-diabetic persons after organ transplantation. The incidence of NODAT vary
by organ transplanted and post-transplant interval. The estimated rates at 12 months post-
transplant are 20-50% for kidney transplants, 9-21% for liver transplants, and approximately
20% for lung transplants [58]. However, a meta-analysis of 56 studies across all organs reported
a 13.5% incidence of NODAT when the diagnosis was made using current guidelines. In
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previous studies using different criteria for the diagnosis of diabetes post-transplant, including
transient peri-operative hyperglycemia, the reported incidence was higher up to 21% in renal
transplant recipients [59]. The risk factors for NODAT are the same as in the general population
with the added effect of immunosuppressive medications, namely corticosteroids, calcineurin
inhibitors and sirolimus. Among calcineurin inhibitors, tacrolimus was found to be more
diabetogenic than cyclosporine [60]. However, both calcineurin inhibitors and steroids play a
major role. Both CNIs have been associated with decreased insulin sensitivity and reduced
insulin release. The reduced insulin release might result from CNI induced damage to
pancreatic beta cells. Comparing the CNIs, most studies show higher rates of post-transplant
diabetes mellitus with tacrolimus use compared to cyclosporine [61]. Other risk factors are
pretx diabetes and obesity. Both pre-existing diabetes and NODAT are important cardiovas‐
cular risk factors, with a 2–5 times increased risk of cardiovascular disease, compared with
transplant recipients without diabetes. In addition, new-onset diabetes is also an independent
risk factor of graft failure and graft loss in kidney transplantation [62]. Monitoring of HbA1C
is not recommended before three months following transplantation because the test may not
be valid until new hemoglobin has been synthesized and glycated for the appropriate period
in the diabetogenic post-transplant setting [63]. The management of post transplant diabetes
follows the principles of treatment in non transplant populations but in addition it often
requires adjustments in the immunosuppression regimens. Although these adjustments should
be weighed against the risk of allograft rejection, options include reduction or weaning of
corticosteroids and switching maintenance immunosuppressive drugs to less diabetogenic
agents.
3.10. Dyslipidemia
The prevalence of dyslipidemia after transplantation has been reported up to 60-70% [64].
The mTOR inhibitors (sirolimus and everolimus, see above) have been associated with
increased risk of dyslipidemia [65]. As hypercholesterolemia has been associated with
increased prevalence of cardiovascular diseases, blood cholesterol levels should be maintained
in the range recommended by practice guidelines, especially in transplant recipients receiving
mTOR inhibitors.
4. Strategies to reduce the burden of immunosuppression and future
directions
Strategies to limit the impact of chronic immunosuppression include protocols of drug
minimization towards individualization of organ-specific immunosuppression regimens,
development of new non-nephrotoxic agents and trials of tolerance induction. Drug minimi‐
zation regimens are being explored in select patient populations to improve the safety of current
immunosuppression protocols while preserving their efficacy. This strategy is based on the
concept that, over time, the risk of rejection decreases and, at the same time, the cumulative
risk for toxicity increases. Studies have concentrated on corticosteroids minimization and
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calcineurin-inhibitors minimization (review in [66]). Careful patient selection and close
monitoring of graft function are mandatory steps for a successful conduct of a drug minimi‐
zation attempt in order to avoid rejection and graft loss.
At present we still lack reliable methods to identify transplant recipients who can be weaned
of immunosuppression, although a number of candidate assays have been proposed to identify
operationally tolerant patients. Among them, transcriptional profiling with either microarray
or real-time PCR is currently a promising approach [67]. Peripheral and intra-graft expression
markers of immune activation are used as tools to guide patient selection and monitor the
progress of drug minimization trials [68]. In renal transplantation, non-invasive urine bio‐
markers have been described by measuring mRNA of inflammatory cytokines [69]. In addition,
studies on urine proteomics allowed to identify different causes of graft dysfunction [70]. These
non-invasive tools with or without protocol allograft biopsy offer the opportunity to monitor
patients enrolled in trials of drug minimization.
In recent years, advances in immunosuppression that target specific pathways of the alloim‐
mune response have been developed (review in [71]). In particular, new medications targeting
the processes related to ischemia-reperfusion injury are currently under evaluation [72]. The
ischemic insult to the allograft associated with the procurement and implantation processes
contributes to trigger the immune activation of the recipient via the release of immunologically
active substances known as damage-associated molecular patterns (DAMPs) [73]. In addition,
new agents are being developed acting on the cellular and humoral mechanisms of the
adaptive immune response. These include antibodies and fusion proteins interfering with T-
cell-mediated activation via LFA-1/ICAM-1, CD2/LFA-3, CD40/CD154, and CD28/B7.1 and
B7.2 interactions [74]. Furthermore, intracellular targets involved in T- and B-cell activation
pathways are being evaluated, including protein kinase C inhibitors, Janus-associated kinase
(JAK) inhibitors, and proteasome inhibitors. Several new medications demonstrate promise in
inhibiting donor-directed humoral immunity by targeting B-cell-activating factor (BAFF) and
complement activation pathways. Finally, other strategies are targeting the “memory”
component of the T-cell repertoire [75] or the regulatory component [76].
Currently, transplant recipients are bound to lifelong immunosuppression. However, there
have been reports of rare instances of “tolerance”, defined as the maintenance of allograft
function without immunosuppression. Although several definitions of tolerance have been
proposed (“complete tolerance”, “prope” tolerance, “operational” tolerance and others) and
consensus is still lacking on the underlying mechanisms involved in tolerance, indeed there
are patients who either intentionally or accidentally fail to reject the allograft and maintain
allograft function while under minimal or no immunosuppression. As an example, in 1993 a
series was reported of 11 liver transplant recipients maintaining normal liver function
following the discontinuation of all immunosuppressive drugs as a consequence of either
noncompliance or lymphoproliferative disorders [77]. Unfortunately, due to the heterogeneity
of the human immune response, it has been so far prohibitively difficult to replicate these
results on a larger number of patients and to establish tolerance in the clinical setting. The
individualization of immunosuppression, identification of biomarkers of tolerance and of
rejection and real-time monitoring of post-transplant immune responses may facilitate
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induction of lasting tolerance in humans [78,79] The advancement of many high-throughput
'omic techniques such as genomics, proteomics and metabolomics has allowed to identify
potential mechanisms of specific graft injury and to develop novel biomarkers for acute
rejection, chronic rejection and operational tolerance [80,81]. Finally, the pharmacogenomics
of organ transplantation has emerged recently as a complement to the immunogenetic
information that has accumulated over the past decade [82]. Polymorphism studies focus on
genes that interact across the group of immunosuppressive drugs (cyclosporin, tacrolimus,
sirolimus and corticosteroids) such as CYP3A5, ABCB1, IMPDH1 and IMPDH2, and cytokines
and growth factors. Although not routinely used in the clinic, it is expected that in the near
future clinical pharmacogenomics techniques will become additional tools in the management
of organ transplant patients.
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